Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Janssen Biotech
Horsham, Pennsylvania, United Statesjanssen.com ↗
- Ownership
- Private
- Employees
- ~7000
- Development stage
- Other
01
Overview
Janssen Biotech, as part of Johnson & Johnson Innovative Medicine, markets multiple FDA-approved drugs in immunology, oncology, infectious disease, and neuroscience. The portfolio includes both first-in-class and best-in-class therapies, with a robust late-stage pipeline and more than 11 new molecular entities approved globally since 2011. Pipeline assets range from preclinical to phase 3, with indications spanning cancers, immunological, and infectious diseases.
- Therapeutic areas
- ImmunologyEndocrinologyInfectious DiseasesPulmonologyDermatologyCardiovascularOncologyNeurology
- Modalities
- Monoclonal antibodySmall moleculeGene therapyVaccineRNA therapyCRISPR-based therapy
- Industry
- Pharma
02
Partnerships
Pipeline TherapeuticsArrowhead PharmaceuticalsLocus Biosciences
Beyond the preview
Go deeper on Janssen Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Janssen Biotech.